

IN THE NATURE OF ABRIDGED PROSPECTUS-MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS



(Please scan this QR code to view the RHP)

This is an abridged prospectus containing salient features of the Red Herring Prospectus of Hannah Joseph Hospital Limited (the “Company”) dated January 14, 2025, filed with the Registrar of Companies, Chennai (the “RHP” or “Red Herring Prospectus”). You are encouraged to read greater details available in the RHP available at <https://hannahjosephhospital.com/>, BRLM at mb@capitalsquare.in and BSE Limited at www.bseindia.com. Unless otherwise specified all capitalised terms used herein and not specifically defined bear the same meaning as ascribed to them in the RHP. This abridged prospectus is not for distribution outside India.

THIS ABRIDGED PROSPECTUS CONSISTS OF BID CUM APPLICATION FORM ALONG WITH INSTRUCTIONS AND 8 PAGES OF ABRIDGED PROSPECTUS. PLEASE ENSURE THAT YOU HAVE RECEIVED ALL THE PAGES



Hannah Joseph Hospital
(Institute of Neurosciences & Trauma)

HANNAH JOSEPH HOSPITAL LIMITED

Corporate Identification Number: U74999TN2011PLC082860 Date of Incorporation: October 24, 2011

REGISTERED OFFICE	CORPORATE OFFICE	CONTACTPERSON	TELEPHONE & E-MAIL	WEBSITE
134, Lake View Road K.K.Nagar, Madurai, Tamil Nadu, India, 625020	Hannah Joseph Hospital Limited RS 115- 3B2, Madurai- Tuticorin Ring Road, Chintamani, Madurai, Madurai North, Tamil Nadu, India, 625009	Yuvaraj Saravanan, Company Secretary & Compliance Officer	Mob. No.: 9524729594 E-mail: cs@hannahjosephhospital.com	https://hannahjosephhospital.com/

THE PROMOTERS OF OUR COMPANY: MOSESJOSEPH ARUNKUMAR, FENN KAVITHA FENN ARUNKUMAR, ARUNKUMAR NALINA AND NOYEL ARUNKUMAR

DETAILS OF ISSUE TO PUBLIC

Type of Issue	Fresh Issue Size	OFS Size	Issue Size	Issue Under	Share Reservation			
					QIB	Non-Institutional Investors	Individual Investors	Market Maker
Fresh Issue	Up to 60,00,000* Equity Shares of the face value of ₹ 10/- each aggregating up to ₹ [●] Lakh	NIL	Up to 60,00,000* Equity Shares aggregating up to ₹ [●] Lakhs	This issue is being made in terms of Regulation 229(2) of Chapter IX of the SEBI (ICDR) Regulations.	Not more than [●] Equity Shares up to ₹ [●] lakhs	Not less than [●] Equity Shares up to ₹ [●] lakhs	Not less than [●] Equity Shares up to ₹ [●]lakhs	[●] Equity Shares up to ₹ [●] lakhs

* Subject to finalization of the Basis of Allotment

These Equity Shares are proposed to be listed on the SME Platform of BSE Limited (i.e. BSE SME)

Details of OFS by Promoter(s)/ Promoter Group/ Other Selling Shareholders: Not Applicable

PRICE BAND, MINIMUM BID LOT & INDICATIVE TIMELINES

Price Band	₹67/- to ₹70/- per Equity Share of Face Value of ₹10/- each
Minimum Bid Lot Size	Minimum 4,000 Equity shares in multiples of 2,000 Equity shares thereafter
Bid/Issue Open On ⁽¹⁾	Thursday, January 22, 2026
Bid/Issue Closes On	Tuesday, January 27, 2026
Finalization of Basis of Allotment with the Designated Stock Exchange	On or about Wednesday, January 28, 2026
Initiation of Allotment / Refunds / Unblocking of Funds from ASBA Account or UPI ID linked bank account*	On or about Thursday, January 29, 2026
Credit of Equity Shares to Demat accounts of Allottees	On or about Thursday, January 29, 2026
Commencement of trading of the Equity Shares on the Stock Exchange	On or about Friday, January 30, 2026

⁽¹⁾Our Company in consultation with the Book Running Lead Manager may consider participation by Anchor Investors in accordance with the SEBI ICDR Regulations. The Anchor Investor Bid/ Issue Period shall be one Working Day prior to the Bid/Issue Opening Date in accordance with the SEBI ICDR Regulations.

*For details of Price Band and Basis of offer Price, please refer to price band advertisement and page 97 of Red Herring Prospectus.

Details of WACA of all shares transacted over the trailing Eighteen Months from the date of RHP

Types of transactions	Weighted average cost of acquisition (Rs. per Equity Shares)	Floor price (i.e. Rs.67)	Cap price (i.e. Rs.70)
WACA of Primary Issuance (except for bonus issue) (exceeding 5% of the pre issue capital)	NA	NA	NA
WACA for secondary sale / acquisition (exceeding 5% of the pre issue capital)	NA	NA	NA
Weighted average cost of acquisition on the last five primary transactions	220.66*	[●]	[●]
Weighted average cost of acquisition on the last five primary transactions	117.27*	[●]	[●]

* Weighted Average Cost of Acquisition has been calculated on fully diluted basis for the trailing three years from the date of Red Herring Prospectus.

RISKS IN RELATION TO THE FIRST OFFER

This being the first public issue of Equity Shares of our Company, there has been no formal market for the Equity Shares. The face value of the Equity Shares is ₹10.00 each. The floor price is ₹ [●] per equity share which is [●] times of the face value and the cap price is ₹ [●] per equity share which is [●] times of the face value. The Floor Price and Cap Price has been determined by our Company, in consultation with the Book Running Lead Manager and Issue Price will be determined by our Company in consultation with the BRLM, on the basis of the assessment of market demand for the Equity Shares by way of the Book Building process, as stated under “*Basis for Issue Price*” on page 97 of the Red Herring Prospectus should not be considered to be indicative of the market price of the Equity Shares after the Equity Shares are listed. No assurance can be given regarding an active or sustained trading in the Equity Shares nor regarding the price at which the Equity Shares will be traded after Listing.

GENERAL RISKS

Investments in Equity and Equity-related securities involve a degree of risk and investors should not invest any funds in this Issue unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Issue. For taking an investment decision, investors must rely on their own examination of our Company and the Issue including the risks involved. The Equity Shares issued in the Issue have not been recommended or approved by the Securities and Exchange Board of India (“SEBI”), nor does SEBI guarantee the accuracy or adequacy of the Red Herring Prospectus. Specific attention of the investors is invited of the section titled “*Risk Factors*” beginning on Page No. 26 of the Red Herring Prospectus.

PROCEDURE

You may obtain a physical copy of the Bid-cum-Application Form and the RHP from the stock exchange, syndicate members, Registrar to the Issue, Depository participants, Stock brokers, Underwriters, Banker to the Offer, Investors’ Associations or Self Certified Syndicate Banks. If you wish to know about processes and procedures applicable to this offer, you may request for a copy of the RHP and/or the General Information Document (GID) from the BRLM or download it from the websites of the Stock Exchange i.e. www.bseindia.com; the BRLM mb@capitalsquare.in and the Company i.e. <https://hannahjosephhospital.com/>

PRICE INFORMATION OF LEAD MANAGER – CAPITALSQUARE ADVISORS PRIVATE LIMITED

Sr. No.	Issuer Name	Issue size (₹ In Lakhs.)	Issue Price (₹)	Listing date	Opening price on listing date	+/- % change in Price on closing price, +/- % change in closing benchmark		
						- 30 th calendar days from listing*	90 th calendar days from listing*	180 th calendar days from listing*
1								

NOT APPLICABLE

PRICE INFORMATION OF LEAD MANAGER – CAPITALSQUARE ADVISORS PRIVATE LIMITED

Name of BRLM and contact details (telephone and email id) of BRLM	CapitalSquare Advisors Private Limited Telephone: 02266849999/ 02266849946 Email ID: mb@capitalsquare.in Contact Person: Viveka Singhal /Pratima Keshari
Name of the Market Maker	CapitalSquare Financial Services Private Limited Telephone: 022 6684 9912 /022 6684 9913 Email ID: mkt.maker@capitalsquare.in Contact Person: Sunil Kumar Manocha
Name of Registrar to the Issue and contact details (telephone and email id)	Bigshare Services Limited Telephone: +91 2262638200 Email ID: ipo@bigshareonline.com Contact Person: Mr. Vinayak Morbale
Name of Statutory Auditor	M/s. A V Subramanian & Co., Chartered Accountants
Name of Credit Rating Agency and the rating or grading obtained, if any	NA
Name of Debenture trustee, if any.	NA
Self-Certified Syndicate Banks	The banks registered with SEBI, offering services, (i) in relation to ASBA (other than through UPI Mechanism), a list of which is available on the website of SEBI at www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=34 or such other website as updated from time to time, and (ii) in relation to ASBA through the UPI Mechanism, a list of which is available on the website of SEBI at https://sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=40 or such other website as updated from time to time. In relation to Bids (other than Bids by Anchor Investor) submitted to a member of the Syndicate, the list of branches of the SCSBs at the Specified Locations named by the respective SCSBs to receive deposits of Bid cum Application Forms from the members of the Syndicate is available on the website of the SEBI at https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=35 and updated from time to time. In accordance with SEBI Circular No. SEBI/HO/CFD/DIL2/CIR/P/2019/76 dated June 28, 2019 and SEBI Circular No. SEBI/ HO/CFD/DIL2/CIR/P/2019/85 dated July 26, 2019, UPI Bidders using the UPI Mechanism may apply through the SCSBs and mobile applications whose names appears on the website of the SEBI at https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=40 and https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=43 respectively, as updated from time to time
Non Syndicate Registered Brokers	You can submit Bid cum Application Forms in the Issue to Non-Syndicate Registered Brokers at the Non-Syndicate Broker Centres. For further details, see section titled “Issue Procedure” beginning at page 256 of the Red Herring Prospectus.

IN THE NATURE OF ABRIDGED PROSPECTUS-MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

Details regarding website address(es)/ link(s) from which the investor can obtain list of registrar to offer and share transfer agents, depository participants and stock brokers who can accept application from investor (as applicable)	The list of the RTAs eligible to accept ASBA Forms at the Designated RTA Locations, including details such as address, telephone number and e-mail address, is provided on the websites of the respective Stock Exchanges at https://www.bseindia.com/Static/PublicIssues/RtaDp.aspx and http://www.nseindia.com/products/content/equities/ipos/asba_procedures.htm , respectively, as updated from time to time.
--	--

PROMOTERS OF THE ISSUER COMPANY

Sr. No.	Name	Individual	Experience & Educational Qualification
1.	Mosesjoseph Arunkumar	Individual	Mosesjoseph Arunkumar aged 58, is the Promoter, Chairman and Managing Director of our Company. He has been associated with our Company since incorporation. He has been re-designated as Managing Director since August 01, 2022. He holds a M.B.B.S. from University of Madras (1989), and Master of Chirurgie in the branch of Neuro Surgery from Dr. M.G.R. Medical University (1999). He also received the Diplomate of National Board, New Delhi (D.N.B.) in Neurosurgery in the year 1999. Mosesjoseph Arunkumar was elected as President of the Tamil Nadu Association of Neurological Surgeons (TANS) in the annual meeting held at Chennai in 2019 for the year 2019-20. He received Best Doctor Award by the Rotary Clubs of Madurai & Media (Vijay TV). In the March 2022 edition of the business magazine CEO Insight Mosesjoseph Arunkumar was on the cover page acclaimed to be "A Neurosurgeon changing the face of Healthcare in Southern Tamil Nadu. The Hindu has Published a Monograph titled 'The Life Story of a Neurosurgeon' by Soma Basuin its Metro Plus edition dated 18th, October 2016 to honour the work of Mosesjoseph Arunkumar. Dr A.P.J. Abdul Kalam Inspiration award for "Most Accomplished Neurosurgeon in Southern India" in 2023, Mosesjoseph Arunkumar featured in India Today's Group "Eminent Doctors South 2024" under Neurosurgery Category and Mosesjoseph Arunkumar has been featured in Outlook Magazine's "Best Doctors South 2025" under the Neurosurgery category. Prior to the incorporation of our Company, *he was associated with the Apollo Speciality Hospital as a full Time Consultant- Neuro surgeon for seven year. Previously, *he held the position of consultant in department of neurosurgery at CMC Hospital, Vellore for one year. He has over 25 years of experience in the field of medicine and healthcare. He is currently responsible for the overall management of the Company
2.	Fenn Kavitha Fenn Arunkumar	Individual	Fenn Kavitha Fenn Arunkumar aged 54, is the Promoter and Whole-time Director of our Company. She has been associated with our Company since incorporation. She has been re-designated as Whole-time Director since August 01, 2022. She holds a MBBS degree from University of Madras (1991) and Diploma in Physiological Medicine from Dr. M.G.R. Medical University. She also received the Diplomate of National Board, New Delhi (D.N.B.) in Psychiatry in the year 2000. She has volunteered as consultant psychiatrist with the NGO Shanti Manas and other 18 NGOs. She is a charter member in all-women rotary organization in Southeast Asia called Rotary Blossom since September 10, 2015. She is also a founder of Youforia Danscool. Prior to the incorporation of our Company, *she was associated with the Apollo Speciality Hospital. She has over 22 years of experience in the field of medicine and healthcare. She is currently responsible for implementing policies of the Company and ensuring that business strategies are executed effectively.
3.	Arunkumar Nalina	Individual	Arunkumar Nalina aged 29, is the Non-Executive Director of our Company. She has been associated with our Company since January 3, 2022. She holds an MBBS degree from Christian Medical College, Vellore (2020). Currently, she has been admitted to the 6-year Neurosurgery program at Christian Medical College, Vellore.
4.	Noyel Arunkumar	Individual	Noyel Arunkumar, aged 24, is the Non- Executive Director of our Company He has been associated with our Company since January 3, 2022. He has completed his schooling from Vikaasa School, Madurai and has joined Shri Satya Sai Medical College and Research Institute in 2020. Chengelpet (Chennai) for pursuing MBBS.

BUSINESS OVERVIEW AND STRATEGY

Business Overview: With an objective to provide comprehensive range of neurosurgery and neurology services, Mosesjoseph Arunkumar established a hospital in the name of 'Hannah Joseph Hospital' as a sole proprietorship in Madurai town of Tamil Nadu, in 2008. On September 9, 2008, the hospital became a member of Nursing Homes and Hospital Board, Indian Medical Association Tamil Nadu State.

Later, the hospital was incorporated as "Hannah Joseph Hospital Private Limited" at Tami Nadu as a private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated October 24, 2011, issued by the Registrar of Companies ("ROC"), Tamil Nadu, Chennai, Andaman and Nicobar Islands Subsequently, our Company was converted to a public limited company and the name of our Company changed to 'Hannah Joseph Hospital Limited' and a fresh certificate of incorporation dated July 29, 2022 was issued by the RoC, Chennai. The CIN of our Company is U74999TN2011PLC082860.

Our Company is being promoted by Mosesjoseph Arunkumar (Neurosurgeon at Hospital), and Fenn Kavitha Fenn Arunkumar (Consultant Psychiatrist at Hospital). Recognizing the demand for increased bed capacity and lack of space, our hospital was relocated in the year 2020. This expansion mark a notable development for our company, signifying sustained growth and progress and holding promising opportunities for future advancements in our healthcare services. Hannah Joseph Hospital Limited, a multi-speciality healthcare provider, strategically located in Madurai, operating in a two acres campus, centrally air-conditioned hospital with central water heating system with a combined bed capacity of 150 beds.

Our Company is a growing organization that aims at strengthening and establishing our presence in healthcare services providers. We strive to serve with our ultra-modern medicinal practices and state of the art infrastructure for medical as well as surgical care solutions. We have been consistently registering phenomenal growth in terms of complicated surgeries, patient volume and turnover making the hospital a landmark for neurosciences in the city of Madurai & south Tamil Nadu. Our medical facility encompasses full-fledged department of neuroradiology by meeting standards of Neurological Institute of International Standard. The Company has also added the department of cardiac sciences with a Cath lab and cardiac operation theatres. The Company now performs complex coronary angioplasties and open-heart Surgeries.

IN THE NATURE OF ABRIDGED PROSPECTUS-MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

We were assessed and found to comply with NABH Accreditation Standards for Hospital 5th edition and has been awarded with a Certificate of Accreditation from National Accreditation Board for Hospitals and Healthcare Provider. Further, we have also received NABL 128 Certification from National Accreditation Board for Testing and Calibration Laboratories.

We are led by our promoter, Mosesjoseph Arunkumar, Chairman and Managing Director and Fenn Kavitha Fenn Arunkumar, Whole Time Director, who has been associated with our Company since inception and has over 2 decades of experience in the field of medicine and healthcare. A dedicated team with a significant experience in the healthcare industry is trained to take care of the patients and handle all kinds of emergencies.

Currently, our primary focus is Neurology, Cardiology, Physchiarty and Trauma healthcare where we have a understanding of global nuances, customer culture and the mindset of medical professionals and where there is a significant need for quality and affordable healthcare services.

We have also partnered with MDIndia Healthcare Services (TPA) Pvt. Ltd. under the Tamil Nadu New Health Insurance Scheme (“TNNHIS”). This scheme facilitates comprehensive cashless medical treatment for employees of Tamil Nadu Government departments, PSU, statutory bodies, undertakings, PSU, statutory boards, State Universities, Noon meal workers, Anganwadi workers, State Govt organization registered under TN registration of societies, TN electricity regulatory commission, TN institute of labor studies under the control of Government of Tamilnadu. As part of this agreement, the hospital commits to provide high-quality medical and surgical care for procedures specified under the scheme. Our key commitments include maintaining robust infrastructure. This partnership highlights our role in delivering accessible and standardized healthcare under the TNNHIS, aligning with the Government’s aim to enhance public health services.

Moreover, we have also entered into a Memorandum of Understanding with the MDIndia Healthcare Services (TPA) Pvt. Ltd. and United India Insurance Co. Ltd to participate in the Chief Minister’s Comprehensive Health Insurance Scheme (“CMCHIS”). This initiative aims to provide cashless health insurance coverage to the family of poor ‘eligible person’. The scheme allows for coverage of up to ₹ 5 lakhs per family per year. It encompasses a wide range of medical procedures, including diagnostic services and specialized treatments. As an empanelled facility, we will provide treatment to eligible beneficiaries identified through the Socio-Economic Caste Census (SECC) database. This includes individuals from various vulnerable groups, such as orphans and differently abled persons. Overall, this collaboration underscores our commitment to enhancing healthcare access for underserved populations in Tamil Nadu.

Particulars	Sept' 25	FY 25	FY 24	FY 23
Revenue Break up				
In-Patient Revenue	2,796.20	5,209.38	4,352.97	3,686.43
Out – Patient Revenue	292.66	526.21	377.70	321.06248
Total	3,088.86	5,735.58	4,730.67	4,007.49
Number of Patients				
In - Patient	656	1413	1,372	1,329
Out – Patient	4,600	7,487	6,377	6,030
Total Number of Patient days	9,284	20,627	18,062	16,812
Average length of stay in days	14	15	13	12
Average revenue per occupied bed (₹)	30,118.49	25,255.13	24,100.16	21,927.36
Average revenue per patient (₹)	58,768.29	64,444.74	61,048.74	54,456.99

As certified by our statutory auditor having peer review certificate M/s A V Subramanian & Co, Chartered Accountant vide their certificate dated January 06, 2026 and UDIN: 26223529CEYHBI7289

Segment / Service-wise break-up of our Revenue from operations is as follows:

(₹ in lakhs)

Particulars	September 30, 2025	March 31, 2025	March 31, 2024	March 31, 2023
Revenue from healthcare services	3088.86	5735.58	4730.67	4007.49
Revenue from pharmacy	1139.32	1965.67	1565.60	1412.54
Revenue from Food sales	26.34	51.87	44.52	42.30
Total	4254.52	7753.13	6340.78	5462.32

Financial Snapshot of our Company as per Restated Financial Information is as under:

(Amount in ₹ Lakhs)

Particulars	As on September 30, 2025	March 31, 2025	March 31, 2024	March 31, 2023
Revenue from Operations	4,254.52	7,753.13	6,340.78	5,462.32
Growth in Revenue from Operations (%)	-	22.27	16.08	(5.98)
Total Income	4,275.47	7,790.05	6,362.81	5,489.68
EBITDA	1,165.02	2,051.96	1,797.75	1,638.07
EBITDA margin (%)	27.38	26.47	28.35	29.99
PAT	511.86	720.99	406.64	101.06
PAT margin (%)	12.03	9.30	6.41	1.85
Return on average equity ("ROAE") (%)	9.39	14.77	10.13	3.41
Return on capital employed("ROCE")(%)	10.41	17.03	13.83	11.35

Intellectual Property, if any: As on date of the Red Herring Prospectus, our Company has registered the following trademarks:

SR. NO.	WORD/ LABEL/ MARK/DESIGN	APPLICATION NO.	CLASS	REGISTRATION/ APPLI CATION DATE	STATUS/ VALIDITY	VALIDITY/ RENEWAL
1.	Hannah Joseph Hospital your faith shall heal  Hannah Joseph Hospital (Institute of Neurosciences & Trauma)	2633743	44	November 27, 2013	Registered	November 27, 2033/ 10 years

IN THE NATURE OF ABRIDGED PROSPECTUS-MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

2.	Hannah Joseph Hospital your faith shall heal  Hannah Joseph Hospital (Institute of Neurosciences & Trauma)	2633744	41	November 27, 2013	Registered	November 27, 2033/ 10 years
----	--	---------	----	-------------------	------------	-----------------------------

Market Share: Not available Manufacturing plant, if any: NA

Employee Strength: As on November 30, 2025, the Company had a workforce of 364 employees.

The following table sets forth a breakdown of our Manpower as on November 30, 2025:

Sr.No.	Particulars	No. of Doctors/Technicians/Nurses/Staff
1.	Full Time Consultants	24
2.	Duty Medical Doctors	15
3.	Visiting Doctors	25
4.	Other Manpower (which includes our Administrative staff, Nurses, Lab Technicians, Therapist, Pharmacist and others)	300
Total		364

For Further Details, please refer chapter titled 'Our Business' on page 119 of the Red Herring Prospectus

BOARD OF DIRECTORS

Sr. No.	Name	Designation	Experience & Educational Qualification	Other Directorships
1.	Mosesjoseph Arunkumar	Managing Director	Mosesjoseph Arunkumar aged 58, is the Promoter, Chairman and Managing Director of our Company. He has been associated with our Company since incorporation. He has been re-designated as Managing Director since August 01, 2022. He holds a M.B.B.S. from University of Madras (1989), and Master of Chirurgie in the branch of Neuro Surgery from Dr. M.G.R. Medical University (1999). He also received the Diplomate of National Board, New Delhi (D.N.B.) in Neurosurgery in the year 1999. Mosesjoseph Arunkumar was elected as President of the Tamil Nadu Association of Neurological Surgeons (TANS) in the annual meeting held at Chennai in 2019 for the year 2019-20. He received Best Doctor Award by the Rotary Clubs of Madurai & Media (Vijay TV). In the March 2022 edition of the business magazine CEO Insight Mosesjoseph Arunkumar was on the cover page acclaimed to be "A Neurosurgeon changing the face of Healthcare in Southern Tamil Nadu. The Hindu has Published a Monograph titled 'The Life Story of a Neurosurgeon' by Soma Basuin its Metro Plus edition dated 18th, October 2016 to honour the work of Mosesjoseph Arunkumar. Dr A.P.J. Abdul Kalam Inspiration award for "Most Accomplished Neurosurgeon in Southern India" in 2023, Mosesjoseph Arunkumar featured in India Today's Group "Eminent Doctors South 2024" under Neurosurgery Category and Mosesjoseph Arunkumar has been featured in Outlook Magazine's "Best Doctors South 2025" under the Neurosurgery category. Prior to the incorporation of our Company, *he was associated with the Apollo Speciality Hospital as a full Time Consultant- Neuro surgeon for seven year. Previously, *he held the position of consultant in department of neurosurgery at CMC Hospital, Vellore for one year. He has over 25 years of experience in the field of medicine and healthcare. He is currently responsible for the overall management of the Company	Public Limited Companies: Nil Private Limited Companies: Nil Foreign Companies: Nil
2.	Fenn Kavitha Fenn Arunkumar	Whole-time Director	Fenn Kavitha Fenn Arunkumar aged 54, is the Promoter and Whole-time Director of our Company. She has been associated with our Company since incorporation. She has been re-designated as Whole-time Director since August 01, 2022. She holds a MBBS degree from University of Madras (1991) and Diploma in Physiological Medicine from Dr. M.G.R. Medical University. She also received the Diplomate of National Board, New Delhi (D.N.B.) in Psychiatry in the year 2000. She has volunteered as consultant psychiatrist with the NGO Shanti Manas and other 18 NGOs. She is a charter member in all-women rotary organization in Southeast Asia called Rotary Blossom since September 10, 2015. She is also a founder of Youforia Danscool. Prior to the incorporation of our Company, *she was associated with the Apollo Speciality Hospital. She has over 22 years of experience in the field of medicine and healthcare. She is currently responsible for implementing policies of the Company and ensuring that business strategies are executed effectively.	Public Limited Companies: Nil Private Limited Companies: Nil Foreign Companies: Nil Other Ventures: Youforia Danscool (Sole Proprietorship)
3.	Arunkumar Nalina	Non- Executive Director	Arunkumar Nalina, aged 29, is the Non Executive Director of our Company. She has been associated with our Company since January 3, 2022. She holds an MBBS degree from Christian Medical College, Vellore (2020). Currently, she has been admitted to the 6 year Neurosurgery program at Christian Medical College, Vellore.	Public Limited Companies: Nil Private Limited Companies: Nil Foreign Companies: Nil
4.	Noyal Arunkumar	Non-Executive Director	Noyal Arunkumar, aged 24, is the Non- Executive Director of our Company He has been associated with our Company since January 3, 2022. He has completed his schooling from Vikaasa School, Madurai and has joined Shri Satya Sai Medical College and Research Institute in 2020. Chengelpet (Chennai) for pursuing MBBS.	Public Limited Companies: Nil Private Limited Companies: Nil Foreign Companies: Nil

IN THE NATURE OF ABRIDGED PROSPECTUS-MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

Sr. No.	Name	Designation	Experience & Educational Qualification	Other Directorships
5.	Chinnamanoor Neelakantan Srinivasan	Independent Director	Chinnamanoor Neelakantan Srinivasan, aged 75 is the Independent Director of our Company. He has been associated with our company with effect from October 10, 2023. He is a qualified Chartered Accountant. He has more than 27 years of experience with a specialisation in Taxation, Corporate and Bank Audits. He was engaged in the diverse areas such as internal audit as well as statutory audit of corporate clients including a few listed companies, audit of non-corporate clients, secretarial matters, preparation of project reports.	Public Limited Companies: Nil Private Limited Companies: Nil Foreign Companies: Nil
6.	Ranganathan Mukundan	Independent Director	Ranganathan Mukundan, aged 72 is the Independent Director of our company. He has been associated with our company with effect from October 10, 2023. He has completed his Bachelor of Commerce from the University of Calcutta in the year 1975. He has obtained a certificate of membership from the Institute of Cost and Works Accountants of India in the year 1979 and has obtained a certificate of membership from the Institute of Company Secretaries in the year 1991. He has more than 12 years of experience as a Practicing Company Secretary. He has immense knowledge in dealing with matters relating to company law, securities law and other corporate transactions.	Public Limited Companies: M R Maniveni Foods Limited 3F Industries Limited Private Limited Companies: Nil Foreign Companies: Nil
7.	Kumarasamy Sureshkumar	Independent Director	Kumarasamy Sureshkumar, aged 60 years, is the Independent Director of our Company. He has been associated with our company with effect from September 05, 2024. He holds a bachelor's degree of Commerce from Madurai Kamraj University (1987) and has obtained a certificate of membership from the Institute of Chartered Accountants of India in the year 2006. He has 19 years of experience in internal audit and he has served as an internal auditor for Tamil Nadu State Transport Corporation, Madurai Region for 3 years and has also served as a statutory branch auditor for, Vilas Bank, Karur Vyasa Bank and Indian Overseas Bank. He has also served as a Concurrent Auditor for Union Bank of India, TMB Ltd., Pandian Gramma Bank, Overseas Bank, Indian Bank, Canara Bank.	Public Limited Companies: Nil Private Limited Companies: Nil Foreign Companies: Nil Other Ventures: K. Sureshkumar & Associates Chartered Accountant
8.	Salaivel Pratheep	Independent Director	Salaivel Pratheep, aged 49 years, is the Independent Director of our Company. He has been associated with our company with effect from September 05, 2024. He holds a Bachelor's Degree of Commerce from Madurai Kamraj University (1998), a Master's Degree in Business Administration from Madurai Kamraj University (2005) and has obtained his Certificate of Practice from the Institute of Chartered Accountants of India in the year 2010. He has also completed his ACCA Diploma in International Financing Reporting in the year 2017. He has 17 years of experience in GST, Banking related domain, Income Tax, various audits like process audit, finance audit, forensic audit and company audit.	Public Limited Companies: Nil Private Limited Companies: Nil Foreign Companies: Nil Other Ventures: Pratheep & Associates Chartered Accountants

OBJECTS OF THE ISSUE

The Issue Comprises of Fresh Issue only

Objects of the Fresh Issue: Our Company proposes to utilize the Net Proceeds from the Issue towards the following objects:

Funding of capital expenditure for establishing Radiation Oncology Centre;

General Corporate Purposes.

The main objects clause and objects incidental and ancillary to the main objects clause are set out in the Memorandum of Association enable us to undertake its existing activities and the activities for which the funds are being raised by us in the Fresh Issue.

Net Proceeds: The details of the proceeds from the Fresh Issue are summarized in the following table:

Particulars	Amount
Gross Proceeds of the Issue	[●]*
Less: Issue related expenses	[●]^
Net Proceeds of the Issue	[●]*

*To be finalized upon determination of the Issue Price and updated in the Prospectus prior to filing with RoC

^ The Public issue related expenses shall vary depending upon the final issue size and the allotment of Equity Shares. For further details, please refer to heading titled 'Issue Related Expenses' of this section title 'Objects of the Issue' of the RHP.

Requirement of Funds and Means of Finance

We intend to finance our Objects of the Issue through Net Proceeds which are as follows:

(₹ in Lakhs)

Sr. No.	Particulars	Amount Required (₹ in Lakhs)	From Net Issue Proceeds	Internal Accruals / Equity / Reserves
1	Acquisition of Land	772.10	0.00	772.10
2	Capital expenditure for establishing Radiation Oncology Centre (other than land)	3,551.71	3,498.21	53.50
3	General Corporate Purposes	[●]	[●]	0.00
4	Issue Related Expenses	[●]	[●]	0.00
	Total	[●]	[●]	825.60

IN THE NATURE OF ABRIDGED PROSPECTUS-MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

Since, the entire fund requirement is to be funded from the proceeds of the Issue, there is no requirement to make firm arrangements of finance under Regulation 230(1)(e) of the SEBI ICDR Regulations through verifiable means towards at least 75% of the stated means of finance, excluding the amounts to be raised through the proposed Issue and existing identifiable internal accruals.

Deployment of Funds and Proposed Schedule of Implementation

The Net Proceeds are proposed to be used in accordance with the details provided in the following table:

(₹ in Lakhs)

Particulars	Total Estimated Cost	Amount to be funded from the Net Issue Proceeds	Amount to be funded from Internal Accruals	Amount already deployed	Estimated Utilization of Net Proceeds Up to	
					Fiscal 2025-26	Fiscal 2026-27
Funding of capital expenditure for establishing Radiation Oncology Centre	4323.81	3,498.21	825.60	772.10	500.00	2998.21
General Corporate Purposes	[•]^	[•]	[•]	[•]	[•]	[•]
Total	[•]	[•]	[•]	[•]	[•]	[•]

^ To be finalized on determination of the Issue Price and updated in the Prospectus prior to filing with the ROC.

The amount utilized for general corporate purposes shall not exceed 15% of the Gross Proceeds of the Issue or ₹ 10 crores whichever is lower.

Means of Finance: Since, the entire fund requirement is to be funded from the proceeds of the Issue, there is no requirement to make firm arrangements of finance under Regulation 230(1)(e) of the SEBI ICDR Regulations through verifiable means towards at least 75% of the stated means of finance, excluding the amounts to be raised through the proposed Issue and existing identifiable internal accruals.

Details and reasons for non-deployment or delay in deployment of proceeds or changes in utilization of issue proceeds of past public issues/rights issue, if any, of the Company in the preceding 10 years - Not Applicable

Name of monitoring agency, if any - Not Applicable

Terms of Issuance of Convertible Security, if any - Not Applicable

SHAREHOLDING PATTERN:

S. No.	Names	No. of equity Shares	As a % of Pre-Issue Capital
Promoters Shareholding			
1.	Mosesjoseph Arunkumar	1,51,62,925	90.80%
2.	Fenn Kavitha Fenn Arunkumar	4,32,000	2.59%
3.	Arunkumar Nalina	15	0.00%*
4.	Noyal Arunkumar	15	0.00%*
Total		1,55,94,955	93.39%
Promoter Group			
1.	James Prabhukumar Moses	29,430	0.18%
2.	Daniel Dayanand Fenn	15	0.00%*
Total		29,445	0.18%
Total shareholding of Promoters and Promoter Group		1,56,24,400	93.57%
Public Shareholding		10,73,963	6.43%
Total Shareholding		1,66,98,363	100.00%

*Negligible Holding

SUMMARY RESTATED AUDITED FINANCIAL

(₹ in lakhs)

Particular	As at and for the Six-months period ended September 30, 2025	As at and for the year ended March 31		
		2025	2024	2023
Share Capital	1,669.84	1,669.84	1,669.84	1,634.97
Reserves and Surplus	4035.69	3523.83	2,901.50	1,820.22
Net Worth ⁽¹⁾	5322.13	4892.56	4,392.80	3,414.52
Revenue from Operation	4254.52	7753.13	6,340.78	5,462.32
Total Income	4275.47	7790.05	6,362.80	5,489.68
Profit After Tax	511.86	720.99	406.64	101.05
Earnings per share (basic and diluted) (Face Value ₹ 10 each) (in ₹)⁽²⁾				
(i) Basic	3.07	4.32	2.47	0.63
(ii) Adjusted	3.07	4.32	2.47	0.63
Net asset value (NAV) per Equity Share (in ₹) ⁽³⁾	31.87	29.30	26.31	20.88
Total borrowings ⁽⁴⁾	3164.08	3357.95	3,138.64	4,295.46

⁽¹⁾Net worth' means aggregate value of the paid-up share capital and other equity created out of the profits, securities premium account and debit or credit balance of profit and loss account, after deducting the aggregate value of the accumulated losses, deferred expenditure and miscellaneous expenditure not written off, derived from Restated Financial Information, but does not include reserves created out of revaluation of assets, write-back of depreciation and amalgamation.

IN THE NATURE OF ABRIDGED PROSPECTUS-MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

⁽²⁾Basic & Adjusted earnings per share (Rs) -Net profit after tax as restated for calculating basic EPS / Weighted average number of equity shares outstanding at the end of the period or year.

⁽³⁾Net assets value per share – Net Worth at the end of the period or year / Total number of equity shares outstanding at the end of the period or year.

⁽⁴⁾Total Borrowing – aggregate value of Long term borrowing and short term borrowings. For further details, see “Restated Financial Statements” on page no. 179.

INTERNAL RISK FACTORS

Below mentioned risks are the top 10 risk factors as per the RHP. For further details, see “Risk Factors” on page 26 of the Red Herring Prospectus:

1. We intend to utilize a portion of the Net Proceeds for setting up the Proposed Radiation Oncology Centre adjacent to the current hospital campus. We are yet to place orders for medical equipments and apply for requisite government approvals for the Proposed Radiation Oncology Centre. If we are unable to commission our Proposed Radiation Oncology Centre without time and cost overruns or unable to adhere to the schedule of implementation, it may adversely affect our business, results of operations and financial conditions.
2. We are required to obtain statutory and regulatory approvals, licenses or permits for our proposed radiation oncology centre. If we fail to obtain, maintain or renew our statutory and regulatory approvals or permits, our business, results of operations, financial condition, and cash flows could be adversely affected
3. There are outstanding legal proceedings involving our Company. Any adverse decisions could impact our net worth, profitability, cashflows and divert management time and attention and have an adverse effect on our business, prospects, results of operations and financial condition.
4. Our Company did not open a separate bank account for private placements made in the past, utilized the proceeds from the issuance prior filing of Form PAS- 3, and issued private placement offer cum application letter before filing the Form MGT-14 with registrar and determined the relevant date within 30 days prior to the date of general meeting in violation of Section 42 of the Companies Act, 2013 and the rules made thereunder, which may have a material adverse effect on our business.
5. While generating the UDIN for the Re-audited financial statements for FY 2023-24, the ‘Certificate’ category was selected due to unavailability of a specific ‘Re-audit’ or ‘Restatement’ option on the ICAI UDIN portal, which may be viewed as a procedural irregularity.
6. There may have been certain instances of irregularities, discrepancies and non-compliances with respect to certain corporate actions taken by our Company in the past. Consequently, we may be subject to regulatory actions and penalties.
7. Our company failed to obtain prior shareholder approval for a loan conversion option as required under Section 62(3) of the Companies Act, 2013 nor did it obtain the necessary valuation report for the same. Any penalty or actions take by regulatory authorities for such non-compliance may have an adverse impact on our business.
8. We are dependent on a number of key personnel, including our Promoters and senior management, and the loss of or our inability to attract or retain such persons could adversely affect our business, financial condition, results of operations and cash flows.
9. Our revenues are significantly dependent on our single hospital in Madurai. Any change in the economic or political circumstances in or around the areas of Madurai, could materially affect our business, financial condition and results of operations.
10. We generate certain revenues from the arrangements with government sponsored health schemes, any adverse change in these regulations/government policies related to such schemes may adversely affect our business, results of operations, cash flows and prospects.

SUMMARY OF OUTSTANDING LITIGATIONS, CLAIMS AND REGULATORY ACTION

Nature of Proceedings	Criminal Proceedings	Tax Proceedings	Statutory or Regulatory Proceedings	Disciplinary actions by the SEBI or Stock Exchanges against our Promoter	Material Civil Litigation	Amount involved *#
Company						
By our Company	Nil	Nil	Nil	Nil	10	16,10,122
Against our Company	Nil	Nil	Nil	Nil	Nil	NA
Directors (other than promoter)						
By our Directors	Nil	Nil	Nil	Nil	Nil	NA
Against our Directors	Nil	Nil	Nil	Nil	Nil	NA
Promoter						
By our Promoter	Nil	Nil	Nil	Nil	Nil	NA
Against our Promoter	Nil	Nil	Nil	Nil	Nil	NA
KMP and SMP						
By our KMP and SMP	Nil	Nil	Nil	Nil	Nil	NA
Against our KMP and SMP	Nil	Nil	Nil	Nil	Nil	NA

*To the extent quantifiable.

#Excludes any interest/penalty in relation to the proceedings.

ANY OTHER IMPORTANT INFORMATION AS PER BRLM / ISSUER COMPANY- NIL

DECLARATION BY THE COMPANY

We, hereby declare that all the relevant provisions of the Companies Act, 2013 and the guidelines issued by the Government of India or the regulations issued by Securities and Exchange Board of India, established under Section 3 of the Securities and Exchange Board of India Act, 1992, as the case may be, have been complied with and no statement made in the Red Herring Prospectus is contrary to the provisions of the Companies Act, 2013, the Securities and Exchange Board of India Act, 1992 or rules made there under or regulations issued there under, as the case may be. We further certify that all statements in the Red Herring Prospectus are true and correct.